Follow
Daniel Renouf
Daniel Renouf
Verified email at bccancer.bc.ca
Title
Cited by
Cited by
Year
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids
L Huang, A Holtzinger, I Jagan, M BeGora, I Lohse, N Ngai, C Nostro, ...
Nature medicine 21 (11), 1364-1371, 2015
7052015
Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial
EM O’Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, G Fisher, ...
JAMA oncology 5 (10), 1431-1438, 2019
4842019
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
M Chan-Seng-Yue, JC Kim, GW Wilson, K Ng, EF Figueroa, GM O’Kane, ...
Nature genetics 52 (2), 231-240, 2020
4272020
Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer
L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ...
Cancer discovery 10 (1), 40-53, 2020
2392020
Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer
EY Zhao, Y Shen, E Pleasance, K Kasaian, S Leelakumari, M Jones, ...
Clinical Cancer Research 23 (24), 7521-7530, 2017
1702017
Nonsmall cell lung carcinoma with neuroendocrine differentiation—an entity of no clinical or prognostic significance
DN Ionescu, D Treaba, CB Gilks, S Leung, D Renouf, J Laskin, ...
The American journal of surgical pathology 31 (1), 26-32, 2007
1702007
Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia
PC McDonald, SC Chafe, WS Brown, S Saberi, M Swayampakula, ...
Gastroenterology 157 (3), 823-837, 2019
1652019
A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors
PC McDonald, S Chia, PL Bedard, Q Chu, M Lyle, L Tang, M Singh, ...
American journal of clinical oncology 43 (7), 484-490, 2020
1632020
Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer
A Kumar, HF Kennecke, DJ Renouf, HJ Lim, S Gill, R Woods, C Speers, ...
Cancer 121 (4), 527-534, 2015
1512015
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
MR Jones, LM Williamson, JT Topham, MKC Lee, A Goytain, J Ho, ...
Clinical Cancer Research 25 (15), 4674-4681, 2019
1432019
Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer
JM Karasinska, JT Topham, SE Kalloger, GH Jang, RE Denroche, ...
Clinical Cancer Research 26 (1), 135-146, 2020
1322020
Ocular toxicity of targeted therapies
DJ Renouf, JP Velazquez-Martin, R Simpson, LL Siu, PL Bedard
Journal of Clinical Oncology 30 (26), 3277-3286, 2012
1322012
Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer
RDA Peixoto, C Speers, CE McGahan, DJ Renouf, DF Schaeffer, ...
Cancer medicine 4 (8), 1171-1177, 2015
1282015
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers
J Laskin, S Jones, S Aparicio, S Chia, C Ch'ng, R Deyell, P Eirew, A Fok, ...
Molecular Case Studies 1 (1), a000570, 2015
1212015
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes
E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ...
Nature Cancer 1 (4), 452-468, 2020
1182020
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
MR Jones, H Lim, Y Shen, E Pleasance, C Ch'ng, C Reisle, ...
Annals of Oncology 28 (12), 3092-3097, 2017
1072017
Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma
K O’Connor, HH Li-Chang, SE Kalloger, RD Peixoto, DL Webber, ...
The American journal of surgical pathology 39 (4), 472-478, 2015
982015
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ...
JAMA oncology 8 (11), 1571-1578, 2022
972022
Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma
T Golan, GM O’Kane, RE Denroche, M Raitses-Gurevich, RC Grant, ...
Gastroenterology 160 (6), 2119-2132. e9, 2021
962021
Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX
RD Peixoto, M Ho, DJ Renouf, HJ Lim, S Gill, JY Ruan, WY Cheung
American journal of clinical oncology 40 (5), 507-511, 2017
832017
The system can't perform the operation now. Try again later.
Articles 1–20